Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“One of the highlights of ESMO25: adjuvant abema significantly improves OS in high-risk ER+ eBC (1.8% OS delta at 7 years).
Benefit enriched in premenopausal patients and those with >10 positive nodes. Updated iDFS curves denote persistent benefit. Practice-confirming.”
More posts about ESMO25.
